Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : How To Write Covered Calls - An Ongoing Real Case Study! -- Ignore unavailable to you. Want to Upgrade?

To: Casaubon who wrote (9535)	1/29/1999 12:53:00 AM
From: Kmartin	Read Replies (2) \| Respond to of 14162

Herm, Help I've run into a problem with a stock, SDTI. It closed today at 24 15/16 and announced missing their number after the bell. Conference call very upbeat and future looks good and they explained the missed number, but... My cost basis is at 20 and I own Feb20 puts to cover all the shares Im long. Im afraid it may drop to the mid teens. Based on fundamentals and the conference call I think Id like to stay in the stock. I HAD some great profits. Can you offer some repair advice. Or do I just get out and start over?

To: Casaubon who wrote (9535)	2/5/1999 5:16:00 PM
From: tuck	Read Replies (3) \| Respond to of 14162

OTEXF and PRXL both look like good plays to me. Rich premies, growing earnings, strong balance sheets, and competing well in businesses with good prospects. Thanks for pointing them out. I accidentally checked out OMKT, too. Two out of four aint bad (premies & business). Actually, the balance sheet isn't too bad. Almost a value play compared to some e-commerce companies :>) The charts look promising to me, too, but I'll leave that analysis to Herm, whose technical analysis skills far surpass my own. Incidentally, VRTX has some competition in the neurotrophic drug department. GLFD was the first one with such compounds that I had heard of, but it turns out that NEOT also has one; it is their lead compound. Both VRTX and NEOT are into clinical trials with their compounds, while GLFD is still in the preclinical stage, but appears to have a broader program. I cannot say I am competent to assess the relative merits of the various candidates, but I can say that the markets they address are quite large; there may be room for all three players. Theses compounds have several indications; one company may be first to market with one indication, while another company could enter later on a different indication. It's possible they could all win for a while. To my knowledge, these three and their partners are the only ones in the game, but omniscient I am not. Anyhow, good luck to you and the rest of us. Cheers, Tuck P.S. Herm, I've been away for a while: what does WINS stand for?